Stereotaxis (NYSE:STXS), a pioneer in innovative robotic technologies for the treatment of arrhythmias and endovascular disease, announced today that it has entered into a definitive agreement to acquire Robocath.
This strategic combination is designed to merge Stereotaxis’ industry-leading magnetic navigation technology with Robocath’s specialized mechanical robotics, creating a unified platform capable of addressing a broad spectrum of procedures across electrophysiology, interventional cardiology, and neurointerventions.
The financial terms of the agreement include an upfront payment of $20 million.
Additionally, the deal provides for contingent payments of up to $25 million based on the achievement of specific regulatory and commercial milestones.
The transaction is expected to close in mid-2026, subject to customary closing conditions.
Stereotaxis anticipates the acquisition will contribute approximately $2 million in revenue during the first year of operation, with a clear path toward reaching breakeven by the third year as the combined technologies scale globally.